Aspira Women's Health Inc. AWHL

Company Overview

Aspira Women’s Health Inc. is a U.S.-based healthcare and molecular diagnostics company focused on gynecologic disease detection and women’s health. The company develops and commercializes blood-based biomarker testing and risk assessment technologies intended to assist physicians in evaluating ovarian cancer risk and managing gynecologic conditions. Aspira operates primarily within the women’s health diagnostics, biotechnology, and precision medicine sectors, with a strategic emphasis on improving early detection and clinical decision-making for ovarian cancer and related diseases.

The company’s primary revenue drivers have historically included diagnostic testing services and related laboratory operations, particularly through its ovarian cancer risk assessment products. Key offerings have included OVA1 and OVERA, which are intended to aid in the assessment of adnexal masses prior to surgical intervention, as well as newer platform initiatives involving artificial intelligence and biomarker-based diagnostics. Aspira traces its origins to Vermillion, Inc., which was founded in the 1990s and later rebranded as Aspira Women’s Health Inc. as the company narrowed its focus toward women’s healthcare diagnostics and technology-enabled disease assessment.